Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration

Alterations in the mesenchymal-epithelial transition factor (<i>MET</i>) gene are critical drivers of non-small cell lung cancer (NSCLC). In recent years advances in precision therapies targeting MET alterations have significantly expanded treatment options for NSCLC patients. These alterations include <i>MET</i> exon 14 skipping mutations (<i>MET</i> exon 14 skipping), <i>MET</i> gene amplifications, <i>MET</i> point mutations (primarily kinase domain mutations), and MET protein overexpression. Accurate identification of these alterations and appropriate selection of patient populations and targeted therapies are essential for improving clinical outcomes. The East China Lung Cancer Group, Youth Committee (ECLUNG YOUNG, Yangtze River Delta Lung Cancer Cooperation Group) has synthesized insights from China's innovative drug development landscape and clinical practice to formulate an expert consensus on the diagnosis and treatment of NSCLC patients with MET alterations. This consensus addresses key areas, such as optimal testing timing, testing methods, testing strategies, quality control measures, and treatment approaches. By offering standardized recommendations, this guidance aims to streamline diagnostic and therapeutic processes and enhance clinical decision-making for NSCLC with MET alterations.

Authors

Institutions

Publication Details

Journal
Cancer Biology and Medicine
Published
2025-04-08
DOI
https://doi.org/10.20892/j.issn.2095-3941.2024.0503
Citations
4
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
6.07
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration

Zhuan Hong, Xinqing Lin, Xiuyu Cai, Jing Cai et al.
4 citations
Cancer Biology and Medicine
Lung Cancer Treatments and Mutations
6.07
article

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration

Zhuan Hong, Xinqing Lin, Xiuyu Cai, Jing Cai, Yanru Xie, Gang Jin, Weiwei Pan, Yina Wang, Xuelei Ma, Yong Fang, Dongqing Lyu, You‐cai Zhu, Zongyang Yu, Fan Wu, Qiming Wang, Bingwei Xu, Ping Zhan, Guansong Wang, Zhefeng Liu, Chengzhi Zhou, Yinbin Zhang, Xuefei Shi, Yuanzhi Lu, Ziming Li, Wenbin Gao, Chunwei Xu, Bing Wan, Hongbing Liu, Liyun Miao, Chuanhao Tang, Kang Zheng, Jinpu Yu, Bihui Li, Xiao‐Dong Jiao, Z.L. Wang, Xingxiang Pu, Yi Shen, Yue Hao, Yingshui Yao, Mingxiang Ye, Lin Wang, Tianshi Lyu, Qi Mei, Yang Xia, Nong Yang, Fei Pang, Zhansheng Jiang, Wen‐Zhao Zhong, Chuangzhou Rao, Xiaomin Niu, Rui Meng, Yao Wang, Wen Li, Wenfeng Li, Ke Wang, Hong Wang, Qian Wang, Dong Wang, Liping Wang, Yuan Li, Zhijie Wang, Song Yang, Kai Wang, Jingjing Liu, Jiandong Wang, Chao Zhang, Zhang Zhang, Wenxian Wang, Xiubao Ren, Yong Song, Ling Xu, Junping Zhang, Jisheng Li, Lin Shi, Zhongwu Li, Yiping Zhang, Zhaofeng Wang, Jianhui Huang, Meizhen Hu, Gen Lin, Xiaoyan Li, Jun Ma, Yongchang Zhang, Long Huang, Shirong Zhang, Wenfeng Fang, Jia‐Tao Zhang, Anwen Liu, Hui Guo, Jin Zhou, Yingying Du, Yanhong Shang, Qian Chu, Gang Lan, Jingxun Wu, Xixu Zhu, Jing Kang, Shenglin Ma, Meiyu Fang, Zhengbo Song, Zhengfei Zhu, Lingfeng Min, Huijing Feng, Lin Wu, Pingli Sun, Dongmei Yuan, D Lyu, Xuewen Liu, Jingping Yuan
article en
4 citations

Abstract

Alterations in the mesenchymal-epithelial transition factor (<i>MET</i>) gene are critical drivers of non-small cell lung cancer (NSCLC). In recent years advances in precision therapies targeting MET alterations have significantly expanded treatment options for NSCLC patients. These alterations include <i>MET</i> exon 14 skipping mutations (<i>MET</i> exon 14 skipping), <i>MET</i> gene amplifications, <i>MET</i> point mutations (primarily kinase domain mutations), and MET protein overexpression. Accurate identification of these alterations and appropriate selection of patient populations and targeted therapies are essential for improving clinical outcomes. The East China Lung Cancer Group, Youth Committee (ECLUNG YOUNG, Yangtze River Delta Lung Cancer Cooperation Group) has synthesized insights from China's innovative drug development landscape and clinical practice to formulate an expert consensus on the diagnosis and treatment of NSCLC patients with MET alterations. This consensus addresses key areas, such as optimal testing timing, testing methods, testing strategies, quality control measures, and treatment approaches. By offering standardized recommendations, this guidance aims to streamline diagnostic and therapeutic processes and enhance clinical decision-making for NSCLC with MET alterations.

Cancer Biology and MedicineVol. 22(3)
Fujian Medical University (CN), Nanjing University of Chinese Medicine (CN), Union Hospital (HK), Central South University (CN), Nanchang University (CN), Army Medical University (CN), Sun Yat-sen University (CN), Jinan University (CN), Guilin Medical University (CN), Shanxi Medical University (CN), Shanghai Jiao Tong University (CN), Anhui Medical University (CN), Chinese Academy of Sciences (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Sichuan University (CN), Fudan University (CN), National Health and Family Planning Commission (CN), Wenzhou Medical University (CN), Nanjing General Hospital of Nanjing Military Command (CN), First Affiliated Hospital of Wenzhou Medical University (CN), Sir Run Run Shaw Hospital (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Shanghai Chest Hospital (CN), Chinese PLA General Hospital (CN), Huzhou Normal University (CN), Wuhan University (CN), Zhengzhou University (CN), First Affiliated Hospital of Xiamen University (CN), Beijing Tian Tan Hospital (CN), Jiaxing University (CN), Fudan University Shanghai Cancer Center (CN), Peking University Cancer Hospital (CN), First Affiliated Hospital of Guangzhou Medical University (CN), 117th Hospital of People's Liberation Army (CN), Jilin Province Tumor Hospital (CN), Zhejiang Cancer Hospital (CN), Shanghai Changzheng Hospital (CN), Shanxi Provincial Cancer Hospital (CN), Huzhou Central Hospital (CN), Second Affiliated Hospital of Nanchang University (CN), Nanjing Drum Tower Hospital (CN), Lishui Central Hospital (CN), Hunan Cancer Hospital (CN), Xinqiao Hospital (CN), Sichuan Cancer Hospital (CN), Fuzhou General Hospital of Nanjing Military Command (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), Zhongshan Hospital (CN), Baotou Central Hospital (CN), Jiangsu Cancer Hospital (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Anhui Provincial Hospital (CN), Second Affiliated Hospital of Xi'an Jiaotong University (CN), Shanghai Chengtou (China) (CN), Second Hospital of Shanxi Medical University (CN), Peking University International Hospital (CN), First Affiliated Hospital of Anhui Medical University (CN), Northern Jiangsu People's Hospital (CN), Second Affiliated Hospital of Nanjing Medical University (CN), First Hospital of Jiaxing (CN), Renmin Hospital of Wuhan University (CN), First Hospital of China Medical University (CN), Affiliated Hospital of Hebei University (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN), Second Affiliated Hospital of Jilin University (CN), Chuxiong Normal University (CN), Henan Cancer Hospital (CN), Guangdong Academy of Medical Sciences (CN), Sun Yat-sen University Cancer Center (CN), Fujian Provincial Cancer Hospital (CN), Jiangsu Province Hospital (CN), Nanjing Jiangning Hospital (CN), Third Xiangya Hospital (CN), Second Affiliated Hospital of Zhejiang University (CN), Zhejiang Taizhou Hospital (CN), Shanxi Academy of Medical Sciences (CN), Tongji Hospital (CN), Baotou Medical College (CN), Qilu Hospital of Shandong University (CN), First Affiliated Hospital of Jinan University (CN), University of Chinese Academy of Sciences (CN), Hangzhou Cancer Hospital (CN), Shenzhen Third People’s Hospital (CN), First Affiliated Hospital Zhejiang University (CN), State Key Laboratory of Biotherapy, State Key Laboratory of Oncology in South China, Huazhong University of Science and Technology (CN), Zhejiang University (CN), Yangzhou University (CN), Taizhou University (CN), Nanjing Medical University (CN), Nanjing University (CN), China Medical University (CN), Guangzhou Medical University (CN), Silicon Labs (United States) (US)
Partnerships for the goals
Openalex Percentile: Top 4%
Lung Cancer Treatments and Mutations
6.07
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.